Our Parkinson's Place: Setback for Newron’s Parkinson med

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Thursday, March 31, 2016

Setback for Newron’s Parkinson med

March 31, 2016

Newron thought it had the US approval for its Parkinson’s treatment Xadafo (safinamide) in the bag. Now, however, the FDA demands to see clinical evaluation of the abuse potential of the drug, further delaying market access.

Italian CNS and pain therapy specialist Newron Pharmaceuticals announced it had received the complete response letter from the US’ Food and Drug Administration (FDA) for safinamide. The letter requested more data on the potential effect of the drug on abuse and dependence effects. “The complete response letter does not require submission of any additional new data/studies/analyses for efficacy or safety in patients with Parkinson’s disease,” Ravi Anand, CMO of Newron, pointed out.

Now, access to the US market is receding into the distance for Newron and its partners Zambon S.p.A., which holds the global marketing rights for Xadago with the exception of Asia. Just two weeks ago, Zambon had announced an agreement with US WorldMeds to commercialise Xadago for the treatment of Parkinson’s disease in the US. “Newron is requesting a meeting with the representatives of the Controlled Substance Staff and Division of Neurological Products to finalise plans for the additional experiments,” added Anand, with a promise of an update in the near future.

Xadafo has already been authorised in the EU, and Zambon has begun commercialisation on the European market.

http://www.european-biotechnology-news.com/news/news/2016-01/setback-for-newrons-parkinson-med.html